Genmab — Maj 2021
-
-
God morgen.
-
Genmab: Partner får godkendt kræftmiddel fra Duobody-platform - GEN: https://www.proinvestor.com/investornyt/675330/genmab-partner-far-godkendt-kraeftmiddel-fra-duobody-platform-gent
-
Asien: Stigninger på baggrund af Wall Street-optimisme
https://www.proinvestor.com/investornyt/675327/asien-stigninger-pa-baggrund-af-wall-street-optimisme -
Tirsdagens aviser med Mærsk, Lunar Bank og Lagkagehuset https://www.proinvestor.com/investornyt/675326/tirsdagens-aviser-med-maersk-lunar-bank-og-lagkagehuset
-
Nordea hæver målkurs til 2606 på baggrund af Rybrevant godkendelse.
-
Det må man sig Hanne.
-
Aktier/tendens: Udsigt til grøn start med fokus på Ambu og Genmab
https://www.proinvestor.com/investornyt/675338/aktier-tendens-udsigt-til-gron-start-med-fokus-pa-ambu-og-genmab -
-
Single digit, formådentlig 5-6%
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind